A recent study showed that moderate to sever dry eye disease can be best treated with anti-inflammatory medications such as topical cyclosporine. According to one ophthalmologist, cyclosporine can significantly limit progression of dry eye disease and should be considered a 'go-to' therapy for this patient population.
The high incidence of neurodegenerative retinal diseases that lead to visual impairment and blindness has given rise to new technological and biological advances in the field of ophthalmology. Electronic retinal prostheses are among the most eagerly anticipated, yet complex devices to be developed. The expertise of retinal specialists, surgeons and engineers has been combined to thoroughly research the effect of electrical stimulation on retinal neurons, to develop micro-electronic chips, investigate new encapsulation methods that are bio-compatible and to develop methods of powering the subretinal devices.
Ophthalmologists who perform refractive procedures today, often to the dismay of patients as well as the treating physicians, achieve less than optimal satisfactory results postoperatively in 5% to 25% of their patients. Residual refractive errors, overcorrection, as well as pre-existing irregular astigmatisms induced by small optical zones and/or decentred ablations are difficult to correct with standard treatments because of their irregular nature.